Preservation of the Liver Graft With Celsior Solution

• Published in: Transplantation proceedings Vol. 38; no. 8; pp. 2385 - 2388
• Main Authors: García-Gil, F.A., Arenas, J., Güemes, A., Esteban, E., Tomé-Zelaya, E., Lamata, F., Sousa, R., Jiménez, A., Barrao, M.E., Serrano, M.T.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: New York, NY Elsevier Inc 01-10-2006; Elsevier Science
• Subjects: Adenosine; Adult; Aged; Allopurinol; Biological and medical sciences; Disaccharides; Electrolytes; Female; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Glutamates; Glutathione; Histidine; Humans; Insulin; Liver; Liver Transplantation - physiology; Male; Mannitol; Medical sciences; Middle Aged; Organ Preservation - methods; Organ Preservation Solutions; Portal Vein - surgery; Postoperative Complications - classification; Postoperative Complications - epidemiology; Prospective Studies; Raffinose; Reperfusion; Reperfusion Injury - epidemiology; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Tissue, organ and graft immunology; Treatment Outcome; Vascular Diseases - epidemiology; Medicine; Organ preservation; Treatment; Preservation; Digestive system; Surgery; Liver; Graft; Transplantation; Homotransplantation
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2006.08.032

We studied the evolution of the liver graft with preservation in Celsior (CS) compared with University of Wisconsin solution (UW).
A randomized prospective clinical study in 80 liver transplants (OLTs) from May 2001 to October 2003, compared CS (group I;
n = 40) and UW (group II;
n = 40). The characteristics of the donors were homogeneous, with no significant differences in 15 variables. CS was perfused with 4 L through the aorta, 2 L through the portal vein, and 1 L, through the portal vein on the back table; and the UW, as 3 L, 2 L, and 1 L, respectively. All OLTs were performed using the piggyback technique.
Group I experienced reperfusion syndrome (
n = 2; 5.9%), primary graft nonfunction (
n = 0); vascular complications (
n = 0); biliary anastomosis stenosis (
n = 8; 22.9%), intensive care unit (ICU) days (
n = 4.1 ± 1), death within 30 days (
n = 1; 3.1%). The patient and graft survivals at 1, 3, 6, 12, and 24 months were 93.7%, 93.7%, 90.2%, 85.7%, 85.7%, and 94.3%, 88.5%, 85.2%, 78%, 78%, respectively. For group II; the reperfusion syndrome occured in 6 patients (17.6%); primary graft nonfunction (
n = 0); vascular complications (
n = 0), biliary anastomosis stenosis (
n = 3; 8.6%), ICU days (
n = 4.9 ± 2.4) and death within 30 days (
n = 1; 3.1%); The patient and graft survival at 1, 3, 6, 12, and 24 months were 96.9%, 93.5%, 89.8%, 79.8%, 79.8% and 94.3%, 88.3%, 84.9%, 75.5%, 66.1%, respectively.
CS offers the similar safety to UW for preservation of liver grafts within these ischemia times.